Search

• Since 2014, several natural history studies and clinical trials have been conducted in centronuclear myopathies (CNM). Many members of international patient organizations dedicated to CNM have been involved as (parents of) participants. • Understanding the participants' experience as well as barriers and facilitators of participation are important to optimize future research and to inform clinical trial management. • The most common barriers to trial participation of patients with various neuromuscular disorders comprise concerns about potential harmful effects, opportunity loss and the expected burden on daily life. • The most common facilitators are an expected benefit on the disease course, altruism and collateral benefit. The limited availability of relevant literature suggest that future research should focus on (qualitative) studies regarding trial experience of CNM patients. The design of a clinical trial for a rare disease can be challenging. An optimal study design is required to effectively study the clinical outcomes for possible therapies for these types of disorders. Understanding the study participants' experiences as well as barriers and facilitators of participation are important to optimize future research and to inform clinical trial management. Centronuclear myopathies (CNMs) including X-linked myotubular myopathy (XLMTM) are a group of rare congenital myopathies for which there is no cure currently. Since 2014, a number of natural history studies and clinical trials have been conducted in CNMs. Two trials have been prematurely terminated because of severe adverse events. Since no research has been conducted regarding trial experience in CNM, we performed a scoping literature research on clinical trial experience of patients with neuromuscular disorders in general. The most common barriers to trial participation of patients comprise concerns about potential harmful effects, opportunity loss and the expected burden on daily life. The most common facilitators were an expected benefit on the disease course, altruism and collateral benefit. While several results are in line with trial experiences of other types of patients, for example oncological patients, distinctions can be made for patients with CNM and other neuromuscular disorders. However, the limited availability of relevant literature suggests that future (qualitative) research should focus on trial experiences in CNM patients. [ABSTRACT FROM AUTHOR]